Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 30,000 shares at $49.00 ($1.5M) on 2025-06-03, disclosed to the SEC on 2025-06-03.
Scheduled sale ($1.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KYMR | SELL | 2026-07-02 | $9.2M | — | Filing → |
| KYMR | SELL | 2026-04-29 | $2.4M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |